RESUMEN
BACKGROUND: Intra bone marrow (IBM) injection has been proposed as a strategy to bypass homing inefficiencies associated with intravenous (IV) hematopoietic progenitor stem cell (HSPC) transplantation and thus increases the number of HSPC that engraft. Despite physical delivery into the bone marrow cavity, many donor cells are rapidly redistributed by vascular perfusion. Thus, the objective of our study was to evaluate the ability of human platelet lysates (hPL) to improve HSPC retention into the bone marrow and consequently to improve engraftment. STUDY DESIGN AND METHODS: HSPC were isolated from human umbilical cord blood. HSPC were seeded in the wells of a 24-well microplate and exposed to increasing concentrations of hPL with or without cytokines for 24 hours. Following priming, HSPC cells chemotaxis to rhSDF-1 was determined in vitro and engraftment in NSG mice was evaluated. RESULTS: Priming of cord blood CD34+ cells to a combination of hPL and cytokines resulted in a significant increase (up to 3-fold) in the expression of the CD34 antigen on HSPC. This effect was closely correlated to a significantly increased (up to 7-fold) migration toward a rhSDF-1 concentration gradient. In addition, IBM injection of CD34+ cells previously primed with hPL+cytokines into NSG mice showed significantly increased engraftment as measured by human platelet numbers, human CD45 and human CD34+ cells for unprimed and primed cells, respectively. CONCLUSION: The use of hPL + cytokines as a short-term priming treatment for UCB could be an advantageous strategy to improve clinical outcomes following IBM injection.
Asunto(s)
Antígenos CD34/sangre , Plaquetas/química , Mezclas Complejas/farmacología , Trasplante de Células Madre de Sangre del Cordón Umbilical , Citocinas/farmacología , Sangre Fetal/metabolismo , Supervivencia de Injerto/efectos de los fármacos , Células Madre de Sangre Periférica/metabolismo , Animales , Mezclas Complejas/química , Femenino , Xenoinjertos , Humanos , Masculino , Ratones , Ratones Endogámicos NOD , Ratones SCIDRESUMEN
Although research on neural tissue repair has made enormous progress in recent years, spinal cord injury remains a devastating condition for which there is still no cure. In fact, recent estimates of prevalence in the United States reveal that spinal cord injury has undergone a five-fold increase in the last decades. Though, it has become the second most common neurological problem in North America after Alzheimer's disease. Despite modern trauma units and intensive care treatments, spinal cord injury remains associated with several comorbid conditions and unbearable health care costs. Regular administration of a plethora of symptomatic drug treatments aimed at controlling related-secondary complications and life-threatening problems in chronic spinal cord-injured patients has recently been reported. This article provides a thorough overview of the main drug classes and products currently used or in development for chronic spinal cord injury. Special attention is paid to a novel class of drug treatment designed to provide a holistic solution for several chronic complications and diseases related with spinal cord injury. There is clear evidence showing that new class can elicit 'on-demand' episodes of rhythmic and stereotyped walking activity in previously completely paraplegic animals and may consequently constitute a simple therapy against several physical inactivity-related comorbid problems. Understanding further pharmacological approaches to chronic spinal cord injury may improve both life expectancy and overall quality of life while reducing unsustainable cost increases associated with this debilitation condition.
Asunto(s)
Traumatismos de la Médula Espinal/complicaciones , Traumatismos de la Médula Espinal/tratamiento farmacológico , Animales , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/etiología , Enfermedad Crónica , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/etiología , Humanos , Actividad Motora/efectos de los fármacos , Espasticidad Muscular/tratamiento farmacológico , Espasticidad Muscular/etiología , Atrofia Muscular/tratamiento farmacológico , Atrofia Muscular/etiología , Neuralgia/tratamiento farmacológico , Neuralgia/etiología , Preparaciones Farmacéuticas/química , Traumatismos de la Médula Espinal/fisiopatología , CaminataRESUMEN
Most animal models of contused, compressed or transected spinal cord injury (SCI) require a laminectomy to be performed. However, despite advantages and disadvantages associated with each of these models, the laminectomy itself is generally associated with significant problems including longer surgery and anaesthesia (related post-operative complications), neuropathic pain, spinal instabilities, deformities, lordosis, and biomechanical problems, etc. This review provides an overview of findings obtained mainly from our laboratory that are associated with the development and characterization of a novel murine model of spinal cord transection that does not require a laminectomy. A number of studies successfully conducted with this model provided strong evidence that it constitutes a simple, reliable and reproducible transection model of complete paraplegia which is particularly useful for studies on large cohorts of wild-type or mutant animals - e.g., drug screening studies in vivo or studies aimed at characterizing neuronal and non-neuronal adaptive changes post-trauma. It is highly suitable also for studies aimed at identifying and developing new pharmacological treatments against aging associated comorbid problems and specific SCI-related dysfunctions (e.g., stereotyped motor behaviours such as locomotion, sexual response, defecation and micturition) largely related with 'command centers' located in lumbosacral areas of the spinal cord.
Asunto(s)
Envejecimiento Prematuro/etiología , Modelos Animales de Enfermedad , Actividad Motora/fisiología , Trastornos del Movimiento/radioterapia , Traumatismos de la Médula Espinal/complicaciones , Traumatismos de la Médula Espinal/tratamiento farmacológico , Envejecimiento Prematuro/tratamiento farmacológico , Envejecimiento Prematuro/metabolismo , Envejecimiento Prematuro/patología , Animales , Proteínas de la Membrana/metabolismo , Ratones , Actividad Motora/efectos de los fármacos , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/metabolismo , Trastornos del Movimiento/patología , Factores de Crecimiento Nervioso/metabolismo , Neuronas/metabolismo , Neuronas/patología , Traumatismos de la Médula Espinal/metabolismo , Traumatismos de la Médula Espinal/patologíaRESUMEN
Intravenous immunoglobulin (IVIg) is a therapeutic preparation of plasma-derived human IgG and is increasingly used for the treatment of several neurological inflammatory disorders. However, it is not clear whether the IgG molecules contained in IVIg can actually cross the BBB in treated patients. We recently showed that LRP1, an endocytic receptor involved in transcytosis of several proteins across the BBB was able to interact with IVIg. In the present study, we show that LRP1 is involved in IVIg internalization inside living cells. Our data also suggest that following internalization, IVIg is recycled to the cell surface, raising the possibility that LRP1 can mediate IVIg transcytosis across the BBB. Finally, we show that IVIg-LRP1 interaction leads to LRP1 tyrosine phosphorylation.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Inmunoglobulinas Intravenosas/metabolismo , Receptores de LDL/metabolismo , Transcitosis , Proteínas Supresoras de Tumor/metabolismo , Animales , Transporte Biológico/fisiología , Línea Celular , Proteína 1 Relacionada con Receptor de Lipoproteína de Baja Densidad , Ratones , Fosforilación/fisiología , Tirosina/metabolismoRESUMEN
BACKGROUND: Chronic spinal cord injury may be complicated by weight loss, muscle atrophy, and bone loss. OBJECTIVE: The authors identified a combination pharmacotherapy using buspirone, carbidopa, and L-DOPA (BCD) that elicits bouts of locomotor-like movements in spinal cord-transected (Tx) mice. They then evaluated the effects of 8 weeks of treadmill training in Tx mice that received BCD or BCD + clenbuterol, a monoaminergic agent with anabolic properties, on locomotor function, muscle atrophy, adipose tissue loss, and bone density measures. METHODS: Induced locomotor movement, adipose tissue, skeletal muscle, and femoral bone properties were compared in unoperated control mice, operated controls (untreated, untrained Tx mice), and 2 groups of treated, trained Tx mice (Tx + BCD, Tx + BCD + clenbuterol) that also received training. RESULTS: BCD- and BCD + clenbuterol-treated mice showed comparable levels of locomotor movements that significantly improved over time. Soleus muscle mass and soleus and extensor digitorum longus cross-sectional area significantly increased in both groups of BCD-treated mice, with greater effects in BCD + clenbuterol-treated animals. Fiber type conversion, adipose tissues, bone mineral density, and content were reduced in all Tx groups compared with unoperated control mice. CONCLUSION: These findings suggest that locomotor movement and muscle properties can be restored to near-normal levels after several weeks of BCD treatment, regular training, and clenbuterol in completely paraplegic animals.
Asunto(s)
Buspirona/uso terapéutico , Dopaminérgicos/uso terapéutico , Terapia por Ejercicio/métodos , Levodopa/uso terapéutico , Paraplejía/tratamiento farmacológico , Paraplejía/rehabilitación , Agonistas de Receptores de Serotonina/uso terapéutico , Tejido Adiposo/efectos de los fármacos , Tejido Adiposo/patología , Análisis de Varianza , Animales , Fenómenos Biomecánicos , Composición Corporal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Densidad Ósea/fisiología , Densitometría , Modelos Animales de Enfermedad , Prueba de Esfuerzo , Antígenos de Histocompatibilidad/metabolismo , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/patología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Paraplejía/etiología , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/fisiología , Región Sacrococcígea , Traumatismos de la Médula Espinal/complicacionesRESUMEN
BACKGROUND: The health benefits associated with physical activity-based rehabilitation in patients with no lower-extremity motor function after a spinal cord injury (SCI) is uncertain. METHODS: The authors assessed signs of efficacy, safety, and utility associated with a novel pharmacological combination therapy to activate central pattern generator (CPG) activity and corresponding locomotor activity in complete thoracic Th9/10-transected mice. RESULTS: Subcutaneous administration 4 times per week for 1 month of 1.5 mg/kg buspirone, 1.5 mg/kg apomorphine, 12.5 mg/kg benserazide, and 50 mg/kg L-DOPA induced episodes of weight-bearing stepping on a treadmill in nonassisted paraplegic mice for 45-minute sessions. Hindlimb muscle cross-sectional area and fiber area values as well as several blood cell constituent levels assessed at 30 days postinjury were positively affected by the combination therapy, as compared with controls. Episodes of locomotion remained effective on each treatment. Femoral bone mineral density loss was not prevented by triple therapy. CONCLUSION: Although translation of these findings needs further experimentation, similar pharmacological activation of the CPG offers a novel therapeutic target to provide some health benefits in motor-complete SCI patients.
Asunto(s)
Terapia por Ejercicio/métodos , Cojera Animal/terapia , Modalidades de Fisioterapia , Traumatismos de la Médula Espinal/rehabilitación , Animales , Terapia Combinada/efectos adversos , Modelos Animales de Enfermedad , Cojera Animal/tratamiento farmacológico , Masculino , Ratones , Parálisis/tratamiento farmacológico , Parálisis/rehabilitación , Traumatismos de la Médula Espinal/tratamiento farmacológicoRESUMEN
Spinal cord injury (SCI) is generally associated with a rapid and significant decrease in muscle mass and corresponding changes in skeletal muscle properties. Although beta(2)-adrenergic and androgen receptor agonists are anabolic substances clearly shown to prevent or reverse muscle wasting in some pathological conditions, their effects in SCI patients remain largely unknown. Here we studied the effects of clenbuterol and testosterone propionate administered separately or in combination on skeletal muscle properties and adipose tissue in adult CD1 mice spinal-cord-transected (Tx) at the low-thoracic level (i.e., induced complete paraplegia). Administered shortly post-Tx, these substances were found to differentially reduce loss in body weight, muscle mass, and muscle fiber cross-sectional area (CSA) values. Although all three treatments induced significant effects, testosterone-treated animals were generally less protected against Tx-related changes. However, none of the treatments prevented fat tissue loss or muscle fiber type conversion and functional loss generally found in Tx animals. These results provide evidence suggesting that clenbuterol alone or combined with testosterone may constitute better clinically-relevant treatments than testosterone alone to decrease muscle atrophy (mass and fiber CSA) in SCI subjects.
Asunto(s)
Clenbuterol/farmacología , Músculo Esquelético/efectos de los fármacos , Paraplejía/metabolismo , Propionato de Testosterona/farmacología , Agonistas Adrenérgicos beta/farmacología , Análisis de Varianza , Andrógenos/farmacología , Animales , Peso Corporal/efectos de los fármacos , Interacciones Farmacológicas , Inmunohistoquímica , Ratones , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Atrofia Muscular/patología , Cadenas Pesadas de Miosina/metabolismo , Paraplejía/patología , Polienos , Distribución AleatoriaRESUMEN
Spinal cord injury (SCI) is a neurological condition, for which no cure exists, typically leading to an immediate and irreversible loss of sensory and voluntary motor functions accompanied by significant health problems. We conducted proof-of-concept experiments aimed at assessing efficacy upon oral administration of a novel combination therapy for central pattern generator (CPG) activation and corresponding locomotor movement generation in completely paraplegic animals. Co-administration orally (by gavage) of buspirone, levodopa and carbidopa was found to dose-dependently induce episodes of steady weight-bearing stepping in low-thoracic (Th9/10) spinal cord-transected (Tx) mice (with no other form of assistance or training). Robust hindlimb stepping with weight-bearing capabilities was induced with the tri-therapy but not with clinically relevant doses of these compounds administered separately. These results provide evidence suggesting that this drug combination may be ideally suited to constitute a first-in-class therapy (CPG activator) for locomotor activity induction in chronic SCI individuals, given that efficacy was shown using commercially available brain-permeable small molecules, already known as safe for the treatment of various neurological indications.
Asunto(s)
Relojes Biológicos/efectos de los fármacos , Buspirona/administración & dosificación , Carbidopa/administración & dosificación , Trastornos Neurológicos de la Marcha/fisiopatología , Levodopa/administración & dosificación , Paraplejía/tratamiento farmacológico , Médula Espinal/fisiopatología , Administración Oral , Animales , Dopaminérgicos/administración & dosificación , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Estudios de Factibilidad , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Trastornos Neurológicos de la Marcha/etiología , Masculino , Ratones , Paraplejía/complicaciones , Paraplejía/fisiopatología , Agonistas de Receptores de Serotonina/administración & dosificaciónRESUMEN
Dopamine (DA) is well-recognized for its determinant role in the modulation of various brain functions. DA was also found in in vitro isolated invertebrate preparations to activate per se the central pattern generator for locomotion. However, it is less clear whether such a role as an activator of central neural circuitries exists in vertebrate species. Here, we studied in vivo the effects induced by selective DA receptor agonists and antagonists on hindlimb movement generation in mice completely spinal cord-transected (Tx) at the low-thoracic level (Th9/10). Administration of D1/D5 receptor agonists (0.5-2.5 mg kg(-1), i.p.) was found to acutely elicit rhythmic locomotor-like movements (LMs) and non-locomotor movements (NLMs) in untrained and non-sensory stimulated animals. Comparable effects were found in mice lacking the D5 receptor (D5KO) whereas D1/D5 receptor antagonist-pretreated animals (wild-type or D5KO) failed to display D1/D5 agonist-induced LMs. In contrast, administration of broad spectrum or selective D2, D3 or D4 agonists consistently failed to elicit significant hindlimb movements. Overall, the results clearly show in mice the existence of a role for D1 receptors in spinal network activation and corresponding rhythmic movement generation.
Asunto(s)
Movimiento , Músculo Esquelético/inervación , Periodicidad , Receptores de Dopamina D1/metabolismo , Traumatismos de la Médula Espinal/metabolismo , Médula Espinal/metabolismo , Nervios Espinales/metabolismo , Animales , Fenómenos Biomecánicos , Modelos Animales de Enfermedad , Agonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/administración & dosificación , Femenino , Miembro Posterior , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Movimiento/efectos de los fármacos , Receptores de Dopamina D1/efectos de los fármacos , Receptores de Dopamina D5/deficiencia , Receptores de Dopamina D5/genética , Médula Espinal/efectos de los fármacos , Médula Espinal/cirugía , Traumatismos de la Médula Espinal/tratamiento farmacológico , Traumatismos de la Médula Espinal/fisiopatología , Nervios Espinales/efectos de los fármacosRESUMEN
A role of serotonin receptors (5-HTRs) in spinal rhythmogenesis has been proposed several years ago based mainly upon data showing that bath-applied 5-HT could elicit locomotor-like rhythms in in vitro isolated spinal cord preparations. Such a role was partially confirmed in vivo after revealing that systemically administered 5-HTR(2) agonists, such as quipazine, could induce some locomotor-like movements (LM) in completely spinal cord-transected (Tx) rodents. However, given the limited binding selectivity of currently available 5-HTR(2) agonists, it has remained difficult to determine clearly if one receptor subtype is specifically associated with LM induction. In situ hybridization, data using tissues from L1-L2 spinal cord segments, where critical locomotor network elements have been identified in mice, revealed greater 5-HTR(2A) mRNA levels in low-thoracic Tx than non-Tx animals. This expression level remained elevated for several days, specifically in the lateral intermediate zone, where peak values were detected at 1 week post-Tx and returned to normal at 3 weeks post-Tx. Behavioral and kinematic analyses revealed quipazine-induced LM in 1-week Tx mice either non-pretreated or pretreated with selective 5-HTR(2B) and/or 5-HTR(2C) antagonists. In contrast, LM completely failed to be induced by quipazine in animals pretreated with selective 5-HTR(2A) antagonists. Altogether, these results provide strong evidence suggesting that 5-HTR(2A) are specifically associated with spinal locomotor network activation and LM generation induced by quipazine in Tx animals. These findings may contribute to design drug treatments aimed at promoting locomotor function recovery in chronic spinal cord-injured patients.
Asunto(s)
Parálisis/metabolismo , Quipazina/farmacología , Receptor de Serotonina 5-HT2A/metabolismo , Traumatismos de la Médula Espinal/metabolismo , Médula Espinal/metabolismo , Animales , Modelos Animales de Enfermedad , Miembro Posterior/inervación , Miembro Posterior/fisiopatología , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Movimiento/efectos de los fármacos , Movimiento/fisiología , Red Nerviosa/efectos de los fármacos , Red Nerviosa/metabolismo , Parálisis/tratamiento farmacológico , Parálisis/fisiopatología , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Receptor de Serotonina 5-HT2A/efectos de los fármacos , Receptor de Serotonina 5-HT2A/genética , Receptor de Serotonina 5-HT2B/efectos de los fármacos , Receptor de Serotonina 5-HT2B/genética , Receptor de Serotonina 5-HT2B/metabolismo , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Receptor de Serotonina 5-HT2C/genética , Receptor de Serotonina 5-HT2C/metabolismo , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/fisiología , Serotonina/metabolismo , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacología , Médula Espinal/efectos de los fármacos , Médula Espinal/fisiopatología , Traumatismos de la Médula Espinal/tratamiento farmacológico , Traumatismos de la Médula Espinal/fisiopatología , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Vértebras Torácicas , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/genéticaRESUMEN
Experiments in completely spinal cord transected (Tx) cats have provided compelling evidence that clonidine combined with tail stimulation can promote locomotor function recovery. However, clonidine has generally failed to induce locomotor activity in other comparable animal models suggesting the existence of species- or condition-specific effects. This study aimed at investigating the effects of clonidine administered (0.25 or 5.0 mg/kg, i.p.) in mice during tail pinching in early (6-7 days post-Tx) or late (41-42 days post-Tx) paraplegic animals (Th9/10 level). Comparisons were made with the effects induced by 8-OH-DPAT (1.0 mg/kg, i.p.), a 5-HT1A/7 receptor agonist known to display prolocomotor effects. Clonidine with or without tail pinching failed to induce hind limb movements and even suppressed the frequency of spontaneously occurring nonlocomotor (NLM) and locomotor-like movements (LM) whereas tail pinching alone (prior to clonidine administration) increased the frequency of spontaneous movements specifically in late chronic animals. In turn, 8-OH-DPAT clearly induced hind limb movements that remained relatively unchanged during tail pinching. Altogether, the results suggest that the prolocomotor effects of clonidine reported elsewhere must depend upon stimuli or factors that remain to be identified.
Asunto(s)
Analgésicos/uso terapéutico , Clonidina/uso terapéutico , Miembro Posterior/fisiopatología , Movimiento/fisiología , Traumatismos de la Médula Espinal/fisiopatología , Cola (estructura animal)/inervación , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Animales , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Relación Dosis-Respuesta a Droga , Prueba de Esfuerzo , Conducta Exploratoria/efectos de los fármacos , Miembro Posterior/efectos de los fármacos , Locomoción/efectos de los fármacos , Ratones , Movimiento/efectos de los fármacos , Estimulación Física/métodos , Recuperación de la Función , Agonistas de Receptores de Serotonina/farmacología , Traumatismos de la Médula Espinal/terapia , Factores de TiempoRESUMEN
A partial recovery of locomotor functions has been shown in spinal cord-transected (Tx) cats after regular treadmill training and repeated administration of clonidine, an alpha(2)-adrenoreceptor agonist. However, clonidine has generally failed to show prolocomotor effects in other models (e.g., rat or mudpuppy in vitro-isolated spinal cord preparations). The reasons for this discrepancy remain unclear, but they may suggest condition- or species-specific effects induced by clonidine. This study is aimed at examining both the acute (at 6 or 41 days post-Tx) and chronic effects of repeated (once a week for one month) clonidine administration (0.25-5.0 mg/kg i.p.) on hindlimb movement generation in Tx mice (thoracic segment9/10). Locomotor-like (LM) and nonlocomotor movements (NLM) were assessed both in open-field and treadmill conditions. The results show that clonidine consistently failed, in both conditions, to induce LM and NLM at all time points even though control experiments revealed hindlimb movements steadily induced by 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH-DPAT), a serotonin receptor agonist. In turn, clonidine acutely suppressed (I(1)-imidazoline receptor-mediated) the frequency of spontaneously occurring LM and NLM but apparently increased spinal excitability over time, because the frequency of spontaneous LM and NLM was significantly greater in clonidine-treated (before an injection) than vehicle-treated animals after repeated administration for a few weeks. The results clearly show that clonidine can not acutely induce hindlimb movements in untrained and otherwise nonstimulated (e.g., no tail or perineal pinching) Tx mice, although repeated administration may progressively facilitate the expression of spontaneous hindlimb movements.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Clonidina/farmacología , Receptores de Imidazolina/fisiología , Movimiento/efectos de los fármacos , Receptores Adrenérgicos alfa 2/fisiología , Traumatismos de la Médula Espinal/fisiopatología , Agonistas de Receptores Adrenérgicos alfa 2 , Antagonistas de Receptores Adrenérgicos alfa 2 , Antagonistas Adrenérgicos alfa/farmacología , Animales , Benzofuranos/farmacología , Miembro Posterior/fisiología , Imidazoles/farmacología , Receptores de Imidazolina/agonistas , Receptores de Imidazolina/antagonistas & inhibidores , Masculino , Ratones , Ratones Endogámicos , Médula Espinal , Yohimbina/farmacologíaRESUMEN
We investigated the roles of the potent, chemotactic antimicrobial proteins S100A8, S100A9, and S100A8/A9 in leukocyte migration in a model of streptococcal pneumonia. We first observed differential secretion of S100A8, S100A9, and S100A8/A9 that preceded neutrophil recruitment. This is partially explained by the expression of S100A8 and S100A9 proteins by pneumocytes in the early phase of Streptococcus pneumoniae infection. Pretreatment of mice with anti-S100A8 and anti-S100A9 Abs, alone or in combination had no effect on bacterial load or mice survival, but caused neutrophil and macrophage recruitment to the alveoli to diminish by 70 and 80%, respectively, without modifying leukocyte blood count, transendothelial migration or neutrophil sequestration in the lung vasculature. These decreases were also associated with a 68% increase of phagocyte accumulation in lung tissue and increased expression of the chemokines CXCL1, CXCL2, and CCL2 in lung tissues and bronchoalveolar lavages. These results show that S100A8 and S100A9 play an important role in leukocyte migration and strongly suggest their involvement in the transepithelial migration of macrophages and neutrophils. They also indicate the importance of antimicrobial proteins, as opposed to classical chemotactic factors such as chemokines, in regulating innate immune responses in the lung.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/antagonistas & inhibidores , Péptidos Catiónicos Antimicrobianos/metabolismo , Calgranulina A/antagonistas & inhibidores , Calgranulina B/inmunología , Inhibición de Migración Celular/inmunología , Fagocitos/inmunología , Neumonía Bacteriana/inmunología , Alveolos Pulmonares/inmunología , Infecciones Estreptocócicas/inmunología , Animales , Anticuerpos Bloqueadores/administración & dosificación , Calgranulina A/inmunología , Calgranulina A/fisiología , Calgranulina B/fisiología , Modelos Animales de Enfermedad , Pulmón/inmunología , Pulmón/metabolismo , Pulmón/ultraestructura , Ratones , Monocitos/inmunología , Monocitos/patología , Infiltración Neutrófila/inmunología , Neutrófilos/inmunología , Neutrófilos/patología , Fagocitos/patología , Neumonía Bacteriana/metabolismo , Neumonía Bacteriana/patología , Alveolos Pulmonares/metabolismo , Alveolos Pulmonares/microbiología , Mucosa Respiratoria/inmunología , Mucosa Respiratoria/patología , Infecciones Estreptocócicas/metabolismo , Infecciones Estreptocócicas/patología , Streptococcus pneumoniae/inmunología , Factores de TiempoRESUMEN
Spinal cord injury (SCI) is associated with the development of deep venous thrombosis (DVT) in the lower limbs and, hence, with rapidly increasing risks of cardiovascular and pulmonary complications soon after trauma. However, specific mechanisms underlying DVT formation following SCI are poorly understood. Here, we studied in mice, employing in vivo confocal microscopy, changes in deep vein size over 4 weeks after spinal cord transection (Tx). Changing levels of biochemical markers that may be associated with DVT formation were also examined. The results showed decreased concentrations of cholesterols, triglycerides, and low-density lipoprotein (LDL), but not of high-density lipoproteins (HDL) and platelets. Concentrations of creatinine, bilirubin, glucose, albumin, total protein and uric acid did not significantly change. In turn, the femoral and saphenous veins underwent a large increase (>1.5-fold) in diameter throughout the entire period studied. Overall, this study reveals that a profound change in deep vein size and, an unsuspected decrease in triglyceride and LDL levels, occur as early as at one week post-Tx in mice. This indicates, given the well-documented risk of DVT formation soon after SCI, that deep vein enlargement, but not lipoprotein level changes, may constitute an early event contributing to venous stasis and thrombi formation in paralyzed individuals.
Asunto(s)
Vena Femoral/patología , Lípidos/sangre , Vena Safena/patología , Traumatismos de la Médula Espinal/sangre , Traumatismos de la Médula Espinal/patología , Trombosis de la Vena/etiología , Animales , Bilirrubina/sangre , Biomarcadores/sangre , Glucemia/metabolismo , Modelos Animales de Enfermedad , Masculino , Ratones , Traumatismos de la Médula Espinal/complicaciones , Vértebras Torácicas , Factores de Tiempo , Trombosis de la Vena/sangre , Trombosis de la Vena/patologíaRESUMEN
Spinal cord injury (SCI) is associated with immune deficiencies and life-threatening infections. However, the specific mechanisms underlying this pathological condition remain unclear. In recent years, increasing evidence has suggested that anabolic hormones may be involved in immunological complications. Here, we monitored candidate hormone concentrations and immune cell counts, in CD1 mice, for 4 weeks after low-thoracic transection of the spinal cord (Tx). Serum dihydroepiandrosterone (DHEA), insulin, and parathyroid hormone (PTH) levels decreased throughout the time period studied compared with control, non-Tx mice. In turn, testosterone and growth hormone (GH) levels were only transiently changed, with a decrease of testosterone during the first 2 weeks and an increase of GH at 1 week post-Tx. A complete blood count revealed either unchanged or moderately decreased erythrocyte, platelet, hemoglobin and hematocrit levels. Total leukocyte, lymphocyte, and eosinophil counts also decreased, whereas neutrophils and monocytes did not change significantly. In the bone marrow, lymphocyte numbers decreased and neutrophils increased, whereas monocytes, eosinophils, and megakariocytes did not change significantly. These results revealed significant changes occurring rapidly (<1-2 weeks) after Tx in both hormonal and immunological systems, providing compelling evidence of a role for anabolic hormones in SCI-related immune deficiencies.
Asunto(s)
Traumatismos de la Médula Espinal/sangre , Traumatismos de la Médula Espinal/inmunología , Animales , Recuento de Células Sanguíneas , Células de la Médula Ósea/fisiología , Deshidroepiandrosterona/sangre , Modelos Animales de Enfermedad , Hormona de Crecimiento Humana/sangre , Insulina/sangre , Masculino , Ratones , Hormona Paratiroidea/sangre , Traumatismos de la Médula Espinal/patología , Testosterona/sangre , Vértebras TorácicasRESUMEN
Recently, proinflammatory activities had been described for S100A8 and S100A9, two proteins found at inflammatory sites and within the neutrophil cytoplasm. In this study, we investigated the role of these proteins in neutrophil migration in vivo in response to LPS. LPS was injected into the murine air pouch, which led to the release of S100A8, S100A9, and S100A8/A9 in the pouch exudates that preceded accumulation of neutrophils. Passive immunization against S100A8 and S100A9 led to a 52% inhibition of neutrophil migration in response to LPS at 3 h postinjection. Injection of LPS was also associated with an increase in peripheral blood neutrophils and the presence in serum of S100A9 and S100A8/A9. Intravenous injection of S100A8, S100A9, or S100A8/A9 augmented the number of circulating neutrophils and diminished the number of neutrophils in the bone marrow, demonstrating that S100A8 and S100A9 induced the mobilization of neutrophils from the bone marrow to the blood. Finally, passive immunization with anti-S100A9 inhibited the neutrophilia associated with LPS injection in the air pouch. These results suggest that S100A8 and S100A9 play a role in the inflammatory response to LPS by inducing the release of neutrophils from the bone marrow and directing their migration to the inflammatory site.
Asunto(s)
Calgranulina A/antagonistas & inhibidores , Calgranulina A/fisiología , Calgranulina B/fisiología , Inhibición de Migración Celular , Lipopolisacáridos/administración & dosificación , Neutrófilos/citología , Neutrófilos/inmunología , Animales , Células de la Médula Ósea/citología , Células de la Médula Ósea/inmunología , Calgranulina A/inmunología , Calgranulina A/metabolismo , Calgranulina B/inmunología , Calgranulina B/metabolismo , Agregación Celular/inmunología , Dimerización , Modelos Animales de Enfermedad , Espacio Extracelular/metabolismo , Inmunoglobulina G/administración & dosificación , Inyecciones Intravenosas , Inyecciones Subcutáneas , Leucocitosis/inmunología , Leucocitosis/metabolismo , Leucocitosis/patología , Leucocitosis/prevención & control , Ratones , Neutrófilos/patología , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacologíaRESUMEN
We investigated the proinflammatory activities of S100A12 in the context of synovial inflammation. S100A12 levels were increased in the synovial fluids and plasma of patients with gout, rheumatoid arthritis, psoriatic arthritis, and undetectable in osteoarthritis, a noninflammatory disorder. S100A12 proved to induce neutrophil adhesion to fibrinogen via Mac-1 at concentrations similar to those found in the synovial fluids. Similar concentrations induced the recruitment of large numbers of neutrophils and monocytes in the murine air pouch model. To characterize the effect of increased S100A12 plasma levels, mice were injected intravenously with S100A12. This led to the mobilization of neutrophils from the bone marrow to the peripheral blood. These results suggest that S100A12 stimulates the accumulation of neutrophil by inducing their release from the bone marrow, as well as by activating their adhesion and migration toward inflammatory sites.
Asunto(s)
Artritis Reumatoide/inmunología , Proteínas de Unión al Calcio/farmacología , Neutrófilos/efectos de los fármacos , Proteínas S100 , Animales , Artritis Reumatoide/metabolismo , Células de la Médula Ósea/citología , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/inmunología , Proteínas de Unión al Calcio/inmunología , Proteínas de Unión al Calcio/metabolismo , Adhesión Celular/efectos de los fármacos , Adhesión Celular/inmunología , Movimiento Celular/efectos de los fármacos , Movimiento Celular/inmunología , Quimiocina CCL4 , Quimiotaxis/inmunología , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Humanos , Proteínas Inflamatorias de Macrófagos/inmunología , Ratones , Neutrófilos/citología , Neutrófilos/inmunología , Conejos , Ratas , Proteína S100A12 , Líquido Sinovial/citología , Líquido Sinovial/inmunologíaRESUMEN
S100A8 and S100A9 are small calcium-binding proteins that are highly expressed in neutrophil and monocyte cytosol and are found at high levels in the extracellular milieu during inflammatory conditions. Although reports have proposed a proinflammatory role for these proteins, their extracellular activity remains controversial. In this study, we report that S100A8, S100A9, and S100A8/A9 caused neutrophil chemotaxis at concentrations of 10(-12)-10(-9) M. S100A8, S100A9, and S100A8/A9 stimulated shedding of L-selectin, up-regulated and activated Mac-1, and induced neutrophil adhesion to fibrinogen in vitro. Neutralization with Ab showed that this adhesion was mediated by Mac-1. Neutrophil adhesion was also associated with an increase in intracellular calcium levels. However, neutrophil activation by S100A8, S100A9, and S100A8/A9 did not induce actin polymerization. Finally, injection of S100A8, S100A9, or S100A8/A9 into a murine air pouch model led to rapid, transient accumulation of neutrophils confirming their activities in vivo. These studies 1) show that S100A8, S100A9, and S100A8/A9 are potent stimulators of neutrophils and 2) strongly suggest that these proteins are involved in neutrophil migration to inflammatory sites.